OraSure Technologies, Inc. – NASDAQ:OSUR
OraSure Technologies stock price today
$2.8
-0.82
-22.65%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
OraSure Technologies stock price monthly change
-15.81%
month
OraSure Technologies stock price quarterly change
-15.81%
quarter
OraSure Technologies stock price yearly change
-56.65%
year
OraSure Technologies key metrics
Market Cap | 271.14M |
Enterprise value | 431.15M |
P/E | -26.58 |
EV/Sales | 1.11 |
EV/EBITDA | -458.67 |
Price/Sales | 1.29 |
Price/Book | 1.38 |
PEG ratio | -1.21 |
EPS | 0.30 |
Revenue | 304.64M |
EBITDA | 15.50M |
Income | 22.85M |
Revenue Q/Q | -65.06% |
Revenue Y/Y | -35.82% |
Profit margin | -4.63% |
Oper. margin | -1.56% |
Gross margin | 38.1% |
EBIT margin | -1.56% |
EBITDA margin | 5.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOraSure Technologies stock price history
OraSure Technologies stock forecast
OraSure Technologies financial statements
| Jun 2023 | 85.44M | -4.79M | -5.61% |
|---|---|---|---|
| Sep 2023 | 89.18M | 11.15M | 12.51% |
| Dec 2023 | 75.88M | 20.07M | 26.45% |
| Mar 2024 | 54.13M | -3.58M | -6.62% |
| Sep 2025 | 43.16M | -2.25M | -5.21% |
|---|---|---|---|
| Oct 2025 | 41.55M | -2.21M | -5.34% |
| Dec 2025 | 42.43M | -3.32M | -7.84% |
| Mar 2026 | 36.55M | -1.47M | -4.05% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 453594000 | 59.45M | 13.11% |
|---|---|---|---|
| Sep 2023 | 458432000 | 16.79M | 3.66% |
| Dec 2023 | 482845000 | 52.17M | 10.81% |
| Mar 2024 | 467558000 | 41.30M | 8.83% |
| Jun 2023 | 57.26M | 37.15M | -632K |
|---|---|---|---|
| Sep 2023 | 11.15M | -2.57M | -705K |
| Dec 2023 | 41.36M | 30.55M | -355K |
| Mar 2024 | 6.73M | -46.52M | -1.29M |
OraSure Technologies alternative data
| Aug 2023 | 840 |
|---|---|
| Sep 2023 | 840 |
| Oct 2023 | 840 |
| Nov 2023 | 840 |
| Dec 2023 | 840 |
| Jan 2024 | 840 |
| Feb 2024 | 840 |
| Mar 2024 | 638 |
| Apr 2024 | 638 |
| May 2024 | 638 |
| Jun 2024 | 638 |
| Jul 2024 | 638 |
OraSure Technologies other data
84.05%
-1.70%
of OSUR is owned by hedge funds
187
+6
61.17M
-988.95K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 100000 | 0 |
| Aug 2023 | 0 | 1758 |
| Dec 2023 | 0 | 24129 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | WEBER KATHLEEN GALLAGHER officer: Chief Pr.. | Non-Qualified Stock Options | 4,129 | $5.72 | $23,597 | ||
Option | WEBER KATHLEEN GALLAGHER officer: Chief Pr.. | Common Stock | 4,129 | $5.72 | $23,597 | ||
Sale | WEBER KATHLEEN GALLAGHER officer: Chief Pr.. | Common Stock | 24,129 | $8.05 | $194,214 | ||
Sale | ANTHONY MICHELE MARIE officer: SVP Finance & CAO | Common Stock | 1,758 | $6.5 | $11,427 | ||
Option | ANTHONY MICHELE MARIE officer: SVP Finance & CAO | Non-Qualified Stock Options | 1,758 | $5.71 | $10,038 | ||
Option | ANTHONY MICHELE MARIE officer: SVP Finance & CAO | Common Stock | 1,758 | $5.71 | $10,038 | ||
Purchase | MCGRATH KENNETH J officer: Chief Financial Officer | Common Stock | 100,000 | $4.93 | $492,800 | ||
Purchase | LANCASTER RONNY B director | Common Stock | 50,000 | $4 | $200,000 | ||
Purchase | GAGLIANO NANCY J director | Common Stock | 2,200 | $4.39 | $9,658 | ||
Purchase | CELANO MICHAEL director | Common Stock | 12,000 | $4.49 | $53,916 |
| Patent |
|---|
Application REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES Filling date: 17 Dec 2021 Issue date: 23 Jun 2022 |
Application Filling date: 9 Dec 2021 Issue date: 16 Jun 2022 |
Application Filling date: 31 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 23 Oct 2019 Issue date: 16 Dec 2021 |
Application Filling date: 8 Aug 2018 Issue date: 26 Nov 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
OraSure Technologies: Multiple Shots To Deliver Value
OraSure Technologies: Historically Cheap
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
OraSure: Valuation Upside On The Table At 16x Forward P/E
OraSure Technologies: As Good As It Gets
March Madness: My Final 4 Small Cap Stocks Under $10
OraSure: Revising To Buy Following Extensive Growth Route
OraSure: Concentration Risk From Covid Revenue, Reaffirm Hold
-
What's the price of OraSure Technologies stock today?
One share of OraSure Technologies stock can currently be purchased for approximately $2.8.
-
When is OraSure Technologies's next earnings date?
Unfortunately, OraSure Technologies's (OSUR) next earnings date is currently unknown.
-
Does OraSure Technologies pay dividends?
No, OraSure Technologies does not pay dividends.
-
How much money does OraSure Technologies make?
OraSure Technologies has a market capitalization of 271.14M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.64% to 405.47M US dollars.
-
What is OraSure Technologies's stock symbol?
OraSure Technologies, Inc. is traded on the NASDAQ under the ticker symbol "OSUR".
-
What is OraSure Technologies's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of OraSure Technologies?
Shares of OraSure Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are OraSure Technologies's key executives?
OraSure Technologies's management team includes the following people:
- Dr. Stephen S. Tang Pres, Chief Executive Officer & Director(age: 64, pay: $1,870,000)
- Ms. Kathleen Gallagher Weber Executive Vice President & Bus. Unit Leader of Molecular Solutions(age: 58, pay: $1,120,000)
- Ms. Lisa Nibauer Executive Vice President & Bus. Unit Leader of Diagnostics(age: 57, pay: $554,850)
-
How many employees does OraSure Technologies have?
As Jul 2024, OraSure Technologies employs 638 workers.
-
When OraSure Technologies went public?
OraSure Technologies, Inc. is publicly traded company for more then 38 years since IPO on 17 Nov 1986.
-
What is OraSure Technologies's official website?
The official website for OraSure Technologies is orasure.com.
-
Where are OraSure Technologies's headquarters?
OraSure Technologies is headquartered at 220 East First Street, Bethlehem, PA.
-
How can i contact OraSure Technologies?
OraSure Technologies's mailing address is 220 East First Street, Bethlehem, PA and company can be reached via phone at +61 8821820.
OraSure Technologies company profile:
OraSure Technologies, Inc.
orasure.comExchange:
NASDAQ
Full time employees:
638
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
220 East First Street
Bethlehem, PA 18015
Bethlehem, PA 18015
CIK: 0001116463
ISIN: US68554V1089
CUSIP: 68554V108
